Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022

Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022

Human medicines European public assessment report (EPAR): Bemrist Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Bemrist Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Selincro, nalmefene, Date of authorisation: 24/02/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Selincro, nalmefene, Date of authorisation: 24/02/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 39, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness